title: Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies.
abstract: Tavaborole, a cyclized boronic acid, has been approved by the Food and Drug Administration for the topical treatment of toenail onychomycosis. This novel, low-molecular-weight pharmaceutical compound has broad-spectrum antifungal activity against dermatophytes, yeasts, and molds responsible for the disease. Tavaborole was tested in 2-year carcinogenicity studies in mice (once daily dermal administration) and rats (once daily by oral gavage) as part of the extensive nonclinical safety program. There was no evidence of tavaborole-related neoplasms observed in either study. Based on the data gathered from these 2 carcinogenicity studies, tavaborole is considered noncarcinogenic.
authors.affiliation: Anacor Pharmaceuticals Inc, Palo Alto, CA, USA vciaravino@anacor.com.
authors.forename: Vic
authors.initials: V
authors.lastname: Ciaravino
authors.affiliation: Anacor Pharmaceuticals Inc, Palo Alto, CA, USA.
authors.forename: Dina
authors.initials: D
authors.lastname: Coronado
authors.affiliation: MPI Research, Inc, Mattawan, MI, USA.
authors.forename: Cheryl
authors.initials: C
authors.lastname: Lanphear
authors.affiliation: ITR Laboratories Canada Inc, Baie d'Urfe, Quebec, Canada.
authors.forename: Imran
authors.initials: I
authors.lastname: Shaikh
authors.affiliation: ITR Laboratories Canada Inc, Baie d'Urfe, Quebec, Canada.
authors.forename: William
authors.initials: W
authors.lastname: Ruddock
authors.affiliation: Anacor Pharmaceuticals Inc, Palo Alto, CA, USA.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Chanda
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000097:blood / Q000633:toxicity*; D001896:Boron Compounds / Q000097:blood / Q000633:toxicity*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000097:blood / Q000633:toxicity*; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D051379:Mice; D014009:Onychomycosis / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012878:Skin Neoplasms / Q000139:chemically induced / Q000473:pathology; D016019:Survival Analysis; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002273:Carcinogens; C512998:tavaborole
keywords: antifungal; carcinogenicity; onychomycosis; tavaborole